crackdown on glp 1 meds FDA ESCALATES: 30 telehealth companies hit with warning letters for false claims compounded GLP-1 drugs. The agency accuses firms of misleading consumers by implying unapproved compounded versions match FDA-approved medications RACGP - TGA doubles down

Medicaid members will pay a $4 copay for brand-name or generic (non-brand name) drugs including over the counter medicine

Phosphorylated Smad3 alters the cytoplasmic pathway and enters the nucleus, where it represses the transcription of fatty acid oxidation genes and induces the transcription of genes related to aberrant glycolysis and fibrogenesis in tubules (Kang et al., 2015)

others provide access to FDA-approved brand-name drugs like Wegovy and Zepbound

Pharmacol Rev (2014) 66(1):179

Tolerability issues such as gastro-intestinal side effects were also cited as a common reason, accounting for around 15% of discontinuations

Limitations of this study include its short 6-week duration, the reliance on self-reported sleep dissatisfaction for recruitment, potential practice effects as both groups showed improvement, and the use of one-tailed significance testing, which can increase the risk of false-positive results